A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Inclusion Criteria: * Subjects of either gender aged ≥ 50 years * Diagnosis of IPCV * Treatment-experienced defined as prior treatment with anti-VEGF mono therapy of ≥ 8 injections in the previous twelve (12) months Exclusion Criteria: * Any intraocular surgery or thermal laser within three (3) months of trial entry * Any prior thermal laser in the macular region, regardless of indication * Any ocular or periocular infection in the twelve (12) weeks prior to entry * History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant * Previous therapeutic radiation in the region of the study eye * A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy and/or leakage from retinal vasculature in a subject with diabetes mellitus)